Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients

NCT02734290 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT02734290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02734290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Lead sponsor
Providence Health & Services
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 23, 2016
Completion date
December 31, 2026
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer